BBY vs STRO · P/E 14, rev $41.53B vs rev $62.0M
Best Buy Co. Inc (BBY) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Best Buy Co. Inc (BBY) is a specialty retail company listed on NYSE.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported BBY revenue for 2025-02-01 was $41.53B. Net income was $927.0M. Revenue was down 4.4% from 2024-02-03 to 2025-02-01. BBY currently screens at market cap $15.41B and trailing P/E 13.5.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
BBY currently screens at market cap $15.41B and trailing P/E 13.5. STRO currently screens at market cap $470.8M.
Not investment advice. Open the BBY and STRO stock pages for the full models.
Not investment advice.